SuperGen Planning Dacogen NDA Submission For Myelodysplastic Syndrome In Third Quarter
This article was originally published in The Pink Sheet Daily
The company plans to begin the fast-track decitabine NDA submission in the second quarter and complete submission in the third quarter. Pharmion’s MDS agent could come to market before then – Vidaza (azacitadine) has a user fee date of June 29.
You may also be interested in...
Mergers with Aesgen and Zycos and a licensing deal with Supergen give MGI pipeline products that dovetail with the sales needs of its existing anti-emetic Aloxi.
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.